LOLLI, CRISTIAN
 Distribuzione geografica
Continente #
NA - Nord America 1.853
EU - Europa 1.277
AS - Asia 726
AF - Africa 109
SA - Sud America 6
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.974
Nazione #
US - Stati Uniti d'America 1.844
IT - Italia 322
SG - Singapore 263
CN - Cina 250
GB - Regno Unito 241
SE - Svezia 176
DE - Germania 141
VN - Vietnam 111
CH - Svizzera 69
IE - Irlanda 66
IN - India 63
RU - Federazione Russa 55
TG - Togo 48
FR - Francia 40
FI - Finlandia 35
UA - Ucraina 30
CI - Costa d'Avorio 28
BG - Bulgaria 22
ZA - Sudafrica 22
EE - Estonia 21
AT - Austria 15
BE - Belgio 15
NL - Olanda 13
ID - Indonesia 9
JO - Giordania 9
NG - Nigeria 9
IR - Iran 7
CA - Canada 5
GR - Grecia 5
HK - Hong Kong 4
NI - Nicaragua 4
PL - Polonia 4
CL - Cile 3
ES - Italia 3
AU - Australia 2
BR - Brasile 2
MY - Malesia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
EG - Egitto 1
IL - Israele 1
JP - Giappone 1
LT - Lituania 1
LU - Lussemburgo 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
SC - Seychelles 1
TR - Turchia 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 3.974
Città #
Chandler 277
Singapore 240
Southend 223
Fairfield 174
Ashburn 155
Santa Clara 103
Wilmington 97
Houston 79
Princeton 72
Dublin 66
Bern 65
Woodbridge 65
Seattle 64
Dong Ket 60
Bologna 58
Cambridge 58
Ann Arbor 57
Boardman 51
Lomé 48
New York 43
Helsinki 34
Turin 29
Abidjan 28
Nanjing 27
Padova 22
Sofia 22
Westminster 22
Berlin 21
Redmond 19
Jinan 17
Rome 17
Milan 16
San Diego 16
Beijing 15
Brussels 15
Munich 12
Vienna 11
Falls Church 10
Jiaxing 10
Amman 9
Des Moines 9
Fort Worth 9
Jakarta 9
Zhengzhou 9
Abeokuta 8
Changsha 8
Norwalk 8
Prineville 8
Ravenna 8
Dearborn 7
Hebei 7
Jacksonville 7
Medford 7
Shanghai 7
Shenyang 7
Bremen 6
Guangzhou 6
London 6
Montescudo 6
Torino 6
Falkenstein 5
Foshan 5
Hangzhou 5
Lanzhou 5
Nanchang 5
Nuremberg 5
Saint Petersburg 5
Yubileyny 5
Bari 4
Fuzhou 4
Hyderabad 4
Los Angeles 4
Managua 4
Mülheim 4
Rolo 4
San Francisco 4
Shijiazhuang 4
Tianjin 4
Toronto 4
Zanjan 4
Bühl 3
Council Bluffs 3
Forlì 3
Frankfurt am Main 3
Hefei 3
Kuban 3
Kunming 3
Monza 3
Paris 3
Phoenix 3
Shenzhen 3
Taiyuan 3
Wenzhou 3
Wuhan 3
Amsterdam 2
Ardabil 2
Cesena 2
Changchun 2
Cinisello Balsamo 2
Dongguan 2
Totale 2.717
Nome #
Follow-up del cancro del pancreas esocrino 309
A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. 212
Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. 163
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 152
Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. 151
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 149
Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). 144
Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. 142
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 132
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib 130
Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. 129
MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFRA kinase genotype. 126
Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. 117
Integrative analysis of gene expression profiling and high-resolution genomic copy number in gastrointestinal stromal tumor (GIST). 116
Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. 108
Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients 106
Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS) 104
Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma 102
CRITICAL ANALYSIS ON MANAGEMENT OF GIST PATIENTS WITH EVENT TREE MODEL 97
SDHA and SDHB mutations in KIT/PDGFRA WT gastrointestinal stromal tumors 96
null 90
The potential role of IGF1r in young adult patients with gastroinetstinal stromal tumor (GIST). 88
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors 84
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 81
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 80
The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: Perspectives for renal cell cancer treatment 79
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 78
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 76
Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. 73
Plasma androgen receptor in prostate cancer 65
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 55
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 47
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 44
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 38
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients 38
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 25
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 24
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 24
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 21
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 21
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 20
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 19
CAR-T cell therapy: A potential new strategy against prostate cancer 17
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 16
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 16
Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics 14
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 14
Psychosocial issues in long-term survivors of testicular cancer 14
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 14
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 10
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 10
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 8
Totale 4.088
Categoria #
all - tutte 11.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.716


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020284 0 0 0 0 0 0 0 85 89 41 34 35
2020/2021400 75 25 5 26 24 27 7 23 39 24 12 113
2021/2022704 59 10 24 49 58 27 40 43 28 66 181 119
2022/2023949 85 158 46 133 47 90 18 47 153 22 62 88
2023/2024303 34 38 22 33 15 72 6 16 24 9 19 15
2024/2025885 79 174 137 120 196 80 58 41 0 0 0 0
Totale 4.088